Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
1.11
Dollar change
+0.07
Percentage change
6.73
%
IndexRUT P/E- EPS (ttm)-0.13 Insider Own0.60% Shs Outstand188.48M Perf Week7.77%
Market Cap209.21M Forward P/E- EPS next Y-0.14 Insider Trans- Shs Float187.35M Perf Month19.34%
Income-23.07M PEG- EPS next Q-0.04 Inst Own48.06% Short Float5.36% Perf Quarter9.90%
Sales8.77M P/S23.86 EPS this Y3.81% Inst Trans0.01% Short Ratio12.67 Perf Half Y-17.78%
Book/sh0.39 P/B2.85 EPS next Y5.94% ROA-19.44% Short Interest10.04M Perf Year-19.57%
Cash/sh0.22 P/C5.06 EPS next 5Y- ROE-31.37% 52W Range0.84 - 1.57 Perf YTD1.83%
Dividend Est.- P/FCF- EPS past 5Y1.87% ROI-32.83% 52W High-29.25% Beta1.27
Dividend TTM- Quick Ratio2.74 Sales past 5Y159.52% Gross Margin86.07% 52W Low31.92% ATR (14)0.07
Dividend Ex-Date- Current Ratio2.74 EPS Y/Y TTM53.40% Oper. Margin-285.11% RSI (14)54.54 Volatility5.41% 8.05%
Employees78 Debt/Eq0.05 Sales Y/Y TTM-36.19% Profit Margin-262.94% Recom1.43 Target Price4.83
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q-14.01% Payout- Rel Volume0.51 Prev Close1.04
Sales Surprise-52.04% EPS Surprise4.08% Sales Q/Q-58.44% EarningsMar 07 AMC Avg Volume792.38K Price1.11
SMA205.45% SMA502.51% SMA200-9.10% Trades Volume404,407 Change6.73%
Date Action Analyst Rating Change Price Target Change
Nov-02-22Initiated Robert W. Baird Outperform $5
Jun-14-22Initiated B. Riley Securities Buy $4
Aug-19-21Initiated Noble Capital Markets Outperform $8
Mar-31-21Initiated Cantor Fitzgerald Overweight $6
Feb-29-24 08:00AM
Feb-13-24 08:00AM
Feb-09-24 09:15AM
Feb-06-24 09:15AM
Jan-16-24 08:00AM
08:00AM Loading…
Dec-18-23 08:00AM
Nov-11-23 04:02PM
Nov-10-23 02:13PM
09:17AM
Nov-09-23 04:01PM
Nov-01-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 05:14PM
Oct-11-23 08:00AM
Oct-05-23 08:00AM
08:00AM Loading…
Sep-19-23 08:00AM
Sep-13-23 08:00AM
Sep-11-23 08:00AM
Sep-06-23 09:40AM
08:00AM
Aug-29-23 08:00AM
Aug-13-23 06:39AM
Aug-11-23 09:43AM
Aug-10-23 05:15PM
04:01PM
Aug-09-23 08:50AM
Aug-08-23 06:40PM
Aug-03-23 08:00AM
Jul-24-23 08:00AM
May-22-23 08:00AM
12:02PM Loading…
May-16-23 12:02PM
May-11-23 05:35PM
04:01PM
May-09-23 08:00AM
May-04-23 06:15PM
08:00AM
Apr-26-23 08:00AM
Apr-18-23 08:00AM
Apr-10-23 07:57PM
Mar-30-23 08:00AM
Mar-28-23 03:57PM
Mar-20-23 08:00AM
Mar-11-23 03:00AM
Mar-10-23 06:33AM
Mar-09-23 05:25PM
04:01PM
Mar-06-23 08:00AM
Mar-02-23 09:55AM
08:00AM
Feb-22-23 09:46AM
08:00AM
Feb-08-23 08:00AM
Nov-29-22 08:00AM
Nov-28-22 08:00AM
Nov-17-22 12:00PM
09:45AM
Nov-10-22 06:35PM
04:05PM
Nov-08-22 05:45PM
Nov-03-22 08:00AM
Oct-31-22 08:00AM
Oct-10-22 08:00AM
Oct-04-22 08:00AM
Oct-03-22 08:00AM
07:41AM
Sep-19-22 07:00AM
Aug-15-22 08:00AM
Aug-12-22 09:30AM
02:31AM
Aug-11-22 04:05PM
Aug-08-22 06:05PM
Aug-04-22 08:00AM
Jul-14-22 08:45AM
Jun-02-22 08:00AM
May-16-22 10:25AM
May-12-22 06:05PM
04:05PM
May-11-22 05:55PM
May-10-22 10:15AM
May-05-22 05:25PM
08:00AM
May-03-22 08:00AM
Apr-26-22 08:00AM
Apr-25-22 08:00AM
Apr-13-22 08:00AM
Apr-11-22 08:00AM
Mar-24-22 08:00AM
Mar-21-22 10:14AM
08:00AM
Mar-14-22 08:00AM
Mar-10-22 06:25PM
04:05PM
Mar-01-22 08:00AM
Feb-28-22 05:25PM
Jan-24-22 08:00AM
Jan-04-22 08:00AM
Dec-20-21 06:03PM
05:02PM
06:00AM
Nov-30-21 08:00AM
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAILEY DON MDirectorFeb 08Buy1.0496,155100,001158,801Feb 08 07:00 PM
BROADWOOD PARTNERS, L.P.DirectorFeb 06Buy1.046,730,7707,000,00141,666,255Feb 08 06:58 PM
Jayasuriya AnulaDirectorDec 29Buy1.0910,00010,90010,000Jan 02 07:08 PM